5 Centers for Medicare and Medicaid Services MEDCAC Meeting 2013.

5 Centers for Medicare and Medicaid Services MEDCAC Meeting 2013.24. Erythopoiesis Stimulating Agents (ESAs in in anemia Related to Kidney Disease ‘See here Accessed 4th March 2011. Source:. Affymax, Takeda Pharmaceuticals North America, Takeda Global Research & Development Center.

Source: Quark Pharmaceuticals,Affymax and Takeda Announce endorsed the submission of an NDA for Peginesatide for the treatment of anemia in dialysis patients with CRFAffymax, Inc. and Takeda Pharmaceutical Company Limited today announced the submission of a New Drug Application with the U.S. Food and Drug Administration for the investigational agent peginesatide . For the treatment of anemia associated with chronic renal failure in adult patients receiving dialysis.Partners will be able exchanging confidential information with, for example, developed the safety of authorized medicines products and or taken for the approval.